Jason A. Amello's departure as Chief Financial Officer of TScan Therapeutics, Inc. was reported, effective September 2, 2026; the filing names no successor. As of November 6, 2026, TScan Therapeutics, Inc. has reported 4 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 2, 2026 to October 16, 2026, naming 1 appointment and 2 departures (Form 8-K, September 2, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like TScan Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-10-16
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-09-11
- · In / out: Out · Person: Jason A. Amello · Role: Chief Financial Officer · Effective: 2026-09-02 · 8-K, 2026-09-02
- · In / out: Out · Person: Leiden Dworak · Role: Vice President · Effective: 2026-04-10 · 8-K, 2026-04-02
TScan Therapeutics, Inc. reported changes in 4 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-02 to 2026-10-16. They name 2 people, with 1 appointment and 2 departures. Every row below is cited to the filing it comes from, and this page adds each new change as TScan Therapeutics, Inc. files it.
Layoffs on record: about 66 jobs, latest 2026-09-02 (layoff filings and notices).
Also on the record for TScan Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 25, 2026 | Stake report, Schedule 13G, by Readout Capital, LP | 5.4% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by BVF PARTNERS L P/IL | 9.99% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Lynx1 Capital Management LP | 13.1% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by BVF PARTNERS L P/IL | 9.99% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Lynx1 Capital Management LP | 15% of the class | 5%+ stakes | Source |
| August 12, 2025 | Stake report, Schedule 13G/A, by Adage Capital Management, L.P. | 2.52% of the class | 5%+ stakes | Source |
| July 16, 2025 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 1.8% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs TScan Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on TScan Therapeutics, Inc. and the records around it.
TScan Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Sep 2026
- Layoff notices Sep 2026
- Who owns it
Companies that share a holder
- Readout Capital, LP also filed stake reports on 1 other company: PRECISION BIOSCIENCES INC (Aug 2025)
- Lynx1 Capital Management LP also filed stake reports on 11 other companies: C4 Therapeutics, Inc. (Aug 2026), GH Research PLC (Aug 2026), iBio, Inc. (Aug 2026)
- BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Olema Pharmaceuticals, Inc. (Oct 2026), Foghorn Therapeutics Inc. (Oct 2026)
Watch TScan Therapeutics, Inc.
Get an email when TScan Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on TScan Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on TScan Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on TScan Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-16 | Reported | not named in the filing | 8-K, 2026-10-16 | ||
| 2026-09-11 | Reported | not named in the filing | 8-K, 2026-09-11 | ||
| 2026-09-02 | Out | Chief Financial Officer | 2026-09-02 | 8-K, 2026-09-02 | |
| 2026-04-02 | Out | Vice President | 2026-04-10 | 8-K, 2026-04-02 | |
| 2026-04-02 | In | Chief Financial Officer | 2026-04-10 | 8-K, 2026-04-02 |
Who leads TScan Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Jason A. Amello, departure reported, effective 2026-09-02 (filed 2026-09-02). No successor is named in these filings.
- Vice President: Leiden Dworak, departure reported, effective 2026-04-10 (filed 2026-04-02). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on TScan Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at TScan Therapeutics, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at TScan Therapeutics, Inc.Every change, in the filing's words
Reported
Resignation of Garry Nicholson and Gabriela Gruia, M.D. On October 13, 2026, each of Garry Nicholson and Gabriela Gruia, M.D., resigned from the Board of Directors (the "Board") of TScan Therapeutics, Inc. (the "Company") and each committee thereof, in each case effective as of October 13, 2026 (the "Resignations").
- Neither Mr. Nicholson's nor Dr. Gruia's resignation was a result of any disagreement with the Company on any matter relating to the Company's operations, practices or policies.
- In connection with the Resignations, the Board appointed Stephen Biggar and R. Keith Woods to the Nominating and Corporate Governance Committee (the "NCG Committee") as member and chairperson, respectively, effective as of October 13, 2026.
- The NCG Committee now consists of R. Keith Woods, Katina Dorton and Stephen Biggar.
- The Audit Committee now consists of Katina Dorton, Barbara Klencke and R. Keith Woods.
Reported
While the Company may elect to update these forward looking statements at some point in the future, the Company specifically disclaims any obligation to do so except as required by law even if new information becomes available in the future.
- On September 8, 2026, the Compensation Committee of the Board of Directors (the "Board") of TScan Therapeutics, Inc. (the "Company") approved a retention program designed to retain the employees required to support the Company, including a key employee retention program (the "Retention Program") that provides for cash awards and the potential future grant of equity-based awards to certain key employees of the Company, including Gavin MacBeath, Ph.D., the Company's Chief Executive Officer, and Zoran Zdraveski, JD, Ph.D., the Company's Chief Legal and Strategy Officer.
- Each of the equity-based awards are to be made under the Company's Amended and Restated 2021 Equity Incentive Plan (the "2021 Plan").
Departing: Jason A. Amello, Chief Financial Officer, effective 2026-09-02
Departure of Certain Officers In connection with the Strategic Reorganization, effective as of September 2, 2026 (the "Effective Date"), the employment of Jason A. Amello, the Company's Chief Financial Officer, and Chrystal Louis, M.D., MPH, the Company's Chief Medical Officer, was terminated.
- Appointment of Principal Financial Officer and Principal Accounting Officer As of the Effective Date, Gavin MacBeath, Ph.D., the Company's Chief Executive Officer, assumed the duties of the principal financial officer and principal accounting officer of the Company.
Departing: Leiden Dworak, Vice President, effective 2026-04-10
On March 31, 2026, Leiden Dworak notified TScan Therapeutics, Inc. (the "Company") of his decision to resign as Vice President of Finance of the Company and principal accounting officer effective April 10, 2026.
Appointed: Jason A. Amello, Chief Financial Officer, effective 2026-04-10
In connection with Mr. Dworak's resignation, the Board of Directors of the Company appointed Jason A. Amello, the Chief Financial Officer and principal financial officer of the Company, as the Company's principal accounting officer, effective April 10, 2026.
- There were no disagreements between the Company and Mr. Dworak relating to the Company's operations, policies or practices.
- Mr. Amello will not receive any additional compensation for assuming the additional role of principal accounting officer, and no changes have been made to any plans or arrangements in which Mr. Amello participates as a result of this appointment.
Tools for this story
Each opens in a new tab, filled in for TScan Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.